GLOBALTHERAPEUTICVACCINES MARKET

Market Shares, Forecasts& Trends

2014 - 2019

mordorintelligence.com

TABLE OF CONTENTS

1. Introduction 1

1.1 Overview 1

1.2 Market Definition 2

1.3 Market Trends 3

2. Executive Summary 4

3. Global Therapeutic Proteins Market – Industry Analysis 5

3.1 Market Drivers 5

3.1.1 Increasing demand ,higher onset of diseases 5

3.1.2 Government funded projects and associations 6

3.1.3 Higher profitability and improved technology 6

3.2 Market opportunities 7

3.2.1 New Target populations- shift from established markets to lesser 8

developed markets

3.3 Market Constraints 9

3.3 .1 Risk of adverse effects 9

3.3.3 High regulatory Intervention and cost 10

4. Types of Vaccines 11

I. Live, attenuated vaccines 11

II. Inactivated vaccines 12

III. Subunit vaccines 13

IV. Toxoid vaccines 14

V. Conjugate vaccines 15

VI. DNA vaccines 16

Global Therapeutic Vaccines Market | Sample

VII. Recombinant vector vaccines 16

5. Vaccine market by application ( Market Size , Forecast, CAGR) 17

5.1 Pediatric Vaccines 17

5.1.1 Pneumococcal 18

5.1.2 Varicella 19

5.1.3 Combinations 20

5.1.3.1 Bivalent 20

5.1.3.2 Trivalent 21

5.1.3.3 Tetravalent 21

5.1.3.4 Pentavalent 22

5.1.4 MMR 23

5.1.5 Poliovirus 24

5.1.6 Hepatitis 25

5.1.7 HIB 26

5.1.8 Other Pediatric 26

5.2 Adult Vaccines 27

5.2.1 Influenza 27

5.2.2 Cervical Cancer 28

5.2.3 Hepatitis 29

5.2.4 Zoster 29

5.2.5 Other adult vaccines 30

6. Regional Analysis of the Vaccine market 31

6.1 North America (Market Size, Forecast and CAGR) 31

6.1.1 USA 31

6.1.2 Canada 32

Global Therapeutic Vaccines Market | Sample

6.1.3 Rest of north America 33

6.2 Europe (Market Size, Forecast and CAGR) 34

6.2.1 Germany 34

6.2.2 France 35

6.2.3 UK 36

6.2.4 Italy 37

6.2.5 Spain 38

6.2.6 Rest of Europe 39

6.3 Asia Pacific (Market Size, Forecast and CAGR) 40

6.3.1 China 40

6.3.2 India 41

6.3.3 Japan 42

6.3.4 Rest of Asia 43

6.4 Rest of the World(Market Size, Forecast and CAGR) 44

7. Competitive Landscape 45

7.1 Current Market trends In Vaccines 45

7.2 Future of Vaccines 46

7.3 Joint Ventures 47

7.4 Mergers and Acquisitions 48

7.5 PentAct HIB, Quinvaxem and the future of Pentavalent vaccines 49

8. Key Company Profiles 50

8.1 SanofiAvnetis 51

8.2 Merck 52

8.3 Glaxosmithkline 53

8.4 Novartis 54

Global Therapeutic Vaccines Market | Sample

8.5 Pfizer 55

8.6 Serum institute 56

9. List Of tables 57

10. List of Figures 58

11. Appendix 59

Global Therapeutic Vaccines Market | Sample

RESEARCH METHODOLOGY

1) Secondary Research: Information was collected from a number of public and paid data sources. Public

sources involved Government websites, publications from the therapeutic vaccine programs of different

countries, company annual reports, white papers and research publications by recognized industry experts, WHO,

Food and drug administration, National cancer Institute, Clinical trials.gov. Paid data sources include authentic

industry databases.

2) Primary Research: After collecting data from secondary sources, primary interviews were conducted with

stakeholders at different points of therapeutic vaccines manufacturers, distributors, ingredient suppliers,

companies manufacturing therapeutic vaccines and key opinion leaders of the industry. 50 respondents

constituting therapeutic vaccines manufacturers, distributors, suppliers, hospital administrators, etc. were

interviewed. The data collected from the survey was analyzed by an expert team of analysts to both validate the

data points obtained from secondary research and to fill any gaps in data.

3) Market Analysis: The market analysis phase involves analyzing the collected data, market breakdown

and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a

complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is

verified by the process of data triangulation to validate the numbers and arrive at a close estimate.

4) Expert Validation: The market analysis data is verified and validated by a number of experts, both in-

house and external.

5) Report Writing: After the data is curated through the process, our analysts begin to write the report.

Garnering insights from data and forecasts, insights are drawn to visualize the entire business ecosystem in a

single report.

Global Therapeutic Vaccines Market | Sample

Global Therapeutic Vaccines Market | Sample

OVERVIEW

The vaccine market accounts for a relatively small share (2-3%) of the global pharmaceutical market sales.

However, there has been rapid growth over recent years, with the vaccine market quadrupling in value from USD 5

billion in 2000 to almost USD 24 billion in 2013. Once a commodity market with low margins, the vaccines on the

market now include blockbusters and mega blockbusters. New candidates for vaccinating against cancers and

HIV are also projected to hit the magic milestone.

Multinational vaccine companies historically have conducted much of the innovation, research, and development

in the field of vaccine production. They have used significant revenues, global size, and deeper expertise to fund.

The development of new technologies for vaccine development – an expensive and relatively time consuming

process. But Despite the success of vaccines, infectious diseases are still a major cause of illnesses worldwide

and at least 40 major infectious diseases are still uncontrolled by vaccination.

There are currently close 120 new vaccines in the pipeline of various companies across the globe set to hit the

market in the next 5 years to come. In anticipation of this and with the emergence of new target market and

smaller player into the market, the Global vaccine market is set to grow by a CAGR of close to 12.4 % till the year

2020.

Source: Mordor Intelligence Analysis

0

5

10

15

20

25

30

2000 2006 2013

Bill

ion

s

Global Vaccine sales( $ billion)

DATA HIDDEN FROM VIEW

Global Therapeutic Vaccines Market | Sample

MARKET DEFINITION

The vaccine Market is different from any other Commodity Market. Compared to the pharmaceutical market it is

relatively small, although growing fast. The vaccine market is rather concentrated on both supply and demand

sides. It is highly regulated and largely dependent on public purchasers and donor policies. The vaccine market

has very distinct features which increase the complexity of assessing and understanding pricing and

procurement in their context. It is made up of individual markets for individual vaccines or vaccine types, each

with their own specificities, particularly on the supply side.

The vaccine market accounts for a relatively small share (2-3%) of the global pharmaceutical market sales.

However, there has been rapid growth over recent years, with the vaccine market quadrupling in value from USD 5

billion in 2000 to almost USD 24 billion in 2013, according to various sources. The market is expected to grow at a

CAGR of 12.4% till 2020, with the arrival of new preventive, therapeutic and adult vaccines.

The market is dominated by 5 major players with Sanofi Pasteur, GSK, Merck, Pfizer, and Novartis being the top

contenders in the market.

Source: company websites

Global Vaccine Majors

MERCK

Pfizer

Global Therapeutic Vaccines Market | Sample

VACCINE MARKET BY APPLICATION (MARKET SIZE, FORECAST, CAGR)

PEDIATRIC VACCINES

Pneumococcal Vaccines

Pneumococcal disease is caused by Streptococcus pneumoniae, a bacterium that has more than 90 serotypes.

Most serotypes cause disease, but only a few produce the majority of invasive pneumococcal disease. The 10

most common types cause 62% of invasive disease worldwide.

There are two major clinical syndromes of invasive pneumococcal disease: bacteremia, and meningitis. They are

both caused by infection with the same bacteria, but have different manifestations.

Pneumococcal pneumonia is the most common disease caused by pneumococcal infection. Pneumococcal

pneumonia can occur in combination with bacteremia and/or meningitis, or it can occur alone. Isolated

pneumococcal pneumonia is not considered invasive disease but it can be severe. It is estimated that 175,000

cases occur each year in the United States. The incubation period is short (1-3 days). Symptoms include abrupt

onset of fever, shaking chills or rigors, chest pain, cough, shortness of breath, rapid breathing and heart rate, and

weakness. The fatality rate is 5%-7% and may be much higher in the elderly. Pneumococcal disease kills more

people in the United States each year than all other vaccine-preventable diseases combined. An estimated 36,850

cases and 4,250 deaths from invasive pneumococcal diseases (bacteremia and meningitis) occurred in the

United States in 2011.

In 2000, the first pneumococcal conjugate vaccine (PCV) was licensed in the U.S. This vaccine contained seven

serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) of Streptococcus pneumoniae and became known as PCV7 (Prevnar

by Wyeth, now Pfizer). Ten years later in February 2010, a new 13-valent product was licensed — PCV13 (Prevnar

13, Pfizer) — which added 6 new serotypes (1, 3, 5, 6A, 7F, and 19A). Together, these 13 serotypes account for the

majority of invasive pneumococcal disease (IPD) in the U.S., including serotype 19A, which is the most common

IPD-causing serotype in young children.

Global Therapeutic Vaccines Market | Sample

The Pneumococcal Vaccine market in 2012 was pinned to be close to $ 4 Billion and is estimated to grow to $8.5

billion by the year 2020. This is touted to be the fastest growing vaccine market in the world, forecasted to grow

at a CAGR of 9.62% during the forecasted period.

Table 1: Pneumococcal Vaccine Market ($ millions)

Region 2012 2013 2014 2020 CAGR

NA XX 836 XX XX XX

Europe 1040 XX XX XX XX

APAC XX XX XX 2380 XX

ROW XX XX XX XX 12

Global XX XX XX XX XX

Source: Mordor Intelligence Analysis

Figure 1

Source: Mordor Intelligence analysis

0

1000

2000

3000

4000

5000

6000

7000

8000

9000

2012 2013 2014 2020

$ M

illio

ns

Pneumococcal Vaccines Market

DATA HIDDEN FROM VIEW

Global Therapeutic Vaccines Market | Sample

The Pneumococcal vaccine market is set to grow at a CAGR of 9.62% during the forecasted period. The

APAC regions and the African regions in the Row are bound to see the maximum growth during this

period, due to the increased acceptance and availability of the vaccine in these markets.

Global Therapeutic Vaccines Market | Sample

DISCLAIMER

Mordor Intelligence Reports and their contents, including all the analysis and research containing valuable

market information, are provided to a select group of customers in response to orders. Our customers

acknowledge when ordering that Mordor Intelligence strategic analysis services are for our customers’ internal

use and not for general publication or disclosure to third parties.

Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation. Mordor

Intelligence takes no responsibility for any incorrect information supplied to us by manufacturers or users.

No part of this strategic analysis service may be given, lent, resold or disclosed to non-customers without written

permission. Reproduction and/or transmission in any form and by any means including photocopying,

mechanical, electronic, recording or otherwise, without the permission of the publisher is prohibited.

ABOUT US

Mordor Intelligence is a global market research and consulting firm. Our singular focus is to provide research

insights for business success.

Our research team has expertise in diverse fields like Agriculture, Healthcare, ICT, Chemicals, Manufacturing,

Logistics, Electronics and Automotive. However diverse the expertise maybe, everyone in our team shares one

common trait - we love data and we love providing solutions to clients using that data even more. Seeing your

business flourish based on our solutions and strategy is what we love the most.

For information regarding permissions and sales, please contact: info@mordorintelligence.com

7 | Mordor Intelligence !

!

Mordor Intelligence LLP No. 30, Padma Nilaya, Chola Nagar Bangalore, Karnataka, India 560032

+1 781 881 1110 | info@mordorintelligence.com

Copyright © 2014 Mordor Intelligence LLP All Rights Reserved. This document contains highly confidential information and is the sole property of Mordor Intelligence LLP. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Mordor Intelligence LLP.